A 51-year-old woman with a history of generalized anxiety disorder (GAD) has been treated with 20 mg of paroxetine (Paxil) for 6 months. The dose was increased to 40 mg at her last visit 2 weeks ago due to increased symptoms of anxiety. Now she reports “hot flashes” and significant hyperhidrosis to her psychiatric mental health nurse practitioner. Which of the following statements is NOT correct about this clinical scenario?

Choice A reason: Dose-dependent hyperhidrosis is a known adverse effect of SSRIs, including paroxetine. This symptom often occurs when the medication dose is increased, reflecting the serotonergic stimulation of the hypothalamic thermoregulatory centers. Therefore, this statement is correct. Choice B reason: SSRIs may be less effective in women over 50 due to age-related hormonal changes, particularly reduced estrogen, which can affect serotonergic pathways and the pharmacodynamics of antidepressants. This statement aligns with clinical observations and is correct. Choice C reason: There is no strong evidence that switching from paroxetine to escitalopram reliably reduces hyperhidrosis. While individual tolerability may differ, recommending a switch solely to mitigate dose-dependent hyperhidrosis is not considered a standard or evidence-based approach. This statement is incorrect in the context of the scenario. Choice D reason: Reducing the dose of paroxetine to the previous effective level and using short-term adjunctive strategies for acute anxiety is an appropriate management plan. Additionally, evaluating hormone levels can provide insight into menopausal or endocrine contributions to symptoms. This approach is evidence-based and correct.